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ergren and Bjo¨rn ErikssSummary An association between severe infant bronchiolitis due to respiratory
syncytial virus (RSV) and subsequent wheezing is well documented. High levels of
urinary eosinophil protein X (U-EPX) have been related to active disease in asthmatic
children. The aim of this study was to analyse whether RSV bronchiolitis leads to an
increase in U-EPX levels and whether wheezing is more common in children with high
U-EPX values.
Seventeen infants requiring in-ward care for verified RSV lower respiratory tract
infection were followed and compared with age-matched controls. A reference
group without a history of RSV bronchiolitis was also included.
At inclusion at mean age 3.3 months and at follow-up at mean age 32.9 months,
U-EPX levels were comparable in the RSV group. However, at follow-up at mean age
6.4 months, the RSV group had significantly increased levels of U-EPX compared with
inclusion (median 167.8; range 46.2–470.7 vs. 122.8; 43.7–266.0 mg/mmol creati-
nine; P ¼ 0:023) and also significantly increased compared with the 6-month-old
controls (167.8 vs. 93.0; 19.0–204.0 mg/mmol creatinine; P ¼ 0:0095). RSV infected
subjects that experienced wheezing had significantly higher U-EPX values both at
inclusion and at age 32.9 months than those who did not. Also, in the reference
group (mean age 18.4 months), the children who had wheezed during the preceding
year had higher U-EPX levels than those who had not wheezed.
In conclusion, RSV bronchiolitis severe enough to require in-ward care produces a
significant, but transient increase in U-EPX. Furthermore, a high U-EPX at baseline
appears to be associated with an increased risk of future wheezing.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
3 3453;
S. Kristja´nsson).
on contributed equally to this work.
ARTICLE IN PRESS
U-EPX and wheezing follwing RSV infection 879Introduction
Respiratory syncytial virus (RSV) is the leading
cause of lower respiratory tract infections (LRTI)
among infants. Wheezing following RSV LRTI is a
well-documented phenomenon.1 The Tucson study
found that obstructive respiratory symptoms fol-
lowing RSV in early childhood tend to diminish
gradually with age until, by the age of 13 years,
they no longer show any significant increase in
prevalence.2 Even so, a tendency towards rever-
sible obstruction was documented.2 The severity of
the original disease and the time of disease onset
might influence the long-term effects, as Sigurs
et al. noted a remaining increase in the risk of
obstructive symptoms at 13 years of age in patients
who had been admitted to hospital for severe RSV
bronchiolitis as infants.3
Th2 lymphocytes, mast cells and eosinophil
granulocytes are crucial components of the
asthmatic inflammation. Upon activation, eosino-
phil granulocytes degranulate and release highly
reactive proteins, including Major Basic Protein
(MBP), Eosinophil Cationic Protein (ECP) and Eosi-
nophil Protein X (EPX). ECP has been used as
a marker of disease and eosinophil activity in
asthma, as well as a method for assessing the
response to glucocorticoid treatment.4–6 ECP can
be measured in serum or nasopharyngeal secre-
tions.7 Urinary (U) EPX is an alternative non-
invasive eosinophil marker in children with asth-
matic symptoms.5,6,8
The aim of this study was to investigate
whether RSV bronchiolitis leads to an increase
in U-EPX levels compared with healthy, age-
matched controls. We also wanted to see
whether there was a relationship between the
levels of U-EPX and the presence of post-infection
wheezing.Table 1 Age, gender characteristics, and presence of a
groups.
Inclusion Age six m
RSV group Controls RSV grou
N 17 12 17
Mean age, months 3.3 3.3 6.4
Male, % 53 67 53
Female, % 47 33 47
Atopic disease in
parents and siblings, %
82 91 82Subjects and methods
Subjects
Seventeen children requiring hospitalization for
RSV bronchiolitis at the Department of Pediatrics,
Landspı´tali University Hospital, Reykjavı´k, Iceland,
were included. RSV infection was diagnosed by
direct (IMAGEN, DakoCytomation) and indirect
(Biotrin, respiratory viral panel) immunofluores-
cent staining of nasopharyngeal aspirates and viral
culture performed at the Department of Virology,
Landspı´tali University Hospital, Reykjavı´k. Samples
of nasopharyngeal secretions were obtained by
passing a polyethylene catheter into the nasophar-
ynx, followed by the application of gentle suction
and rinsing into collection traps containing 2.5mL
of saline.
The age and gender characteristics of the infants
are shown in Table 1. Median weight at birth was
3400 g (range 1665–4600 g) and the median length
was 50 cm (range 43–55 cm). A follow-up of the
children was made after 3 and 30 months. At the
follow-up after 30 months, parents were asked to
fill out a semi-structured questionnaire relating to
wheezing during the preceding 12-month period. If
wheezing had occurred, the number of times was
noted. Parents were also questioned about the
presence of atopic disease (atopic dermatitis,
asthma, allergic rhinoconjunctivitis or food allergy)
among themselves and siblings (Table 1).
Two separate groups of age-matched, healthy
controls of 3 and 6 months (n ¼ 12 and 13,
respectively) were randomly recruited from the
Centre for Child Health Services in Reykjavı´k and
investigated correspondingly (Table 1). In addition,
a reference group of 25 children without a history
of RSV bronchiolitis, mean age 18.4 months, was
randomly recruited from the Centre for Childtopic disease among parents and siblings in the study
onths Age 33 months Non-bronchiolitis
reference group
p Controls RSV group
13 17 25
6 32.9 18.4
46 53 68
54 47 32
82 82 80
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Figure 1 Median U-EPX levels for RSV infected subjects
and controls at different time points.
S. Kristja´nsson et al.880Health Services (Table 1). Also, these parents were
asked to fill out a semi-structured questionnaire
relating to wheezing during the preceding 12-
month period. If wheezing had occurred, the
number of times was noted. Parents were also
questioned about the presence of atopic disease
among themselves and siblings.
U-EPX measurements and white blood cell
counts
U-EPX levels were determined in all children at all
time points. In the RSV group the first U-EPX
samples were obtained during the RSV infection
within 24 h from admission. Urine samples were
collected and stored at 20 1C until measurements
were performed. Due to the diurnal variation in U-
EPX, samples were taken between 9 and 12 a.m.9
U-EPX levels were measured with a radioimmu-
noassay with a detection limit of approximately
3 mg/L (Pharmacia Diagnostics, Uppsala, Sweden)
and related to urinary creatinine concentration
(Jaffe´’s reaction, HiCo Creatinine, Boehringer
Mannheim GmbH, Germany) to compensate for
urinary water dilution. Venous blood was obtained,
and analysed the same day. The white blood cell
and differential counts were analysed using Cell-
Dyn 4000 (USA System, Santa Clara, CA, USA).
Skin prick test
Thirty months after inclusion, at mean age 32.9
months, all children in the RSV group were
examined with a skin prick test. The SPT included
the following allergens: Dermatophagoides farinae,
Dermatophagoides pteronyssinus, grass pollen,
dog, cat, cow’s milk (raw and boiled), egg white,
peanuts, wheat, fish (cod) and soy. The extracts of
the ALK Solupricks kit (ALK, Hørsholm, Denmark)
were used. Skin prick test was also performed in
the 18-month-old children recruited from the
Centre for Child Health Services.
Statistical analysis
Statistical analyses were conducted using the
JMPTM software (SAS Institute Inc., Cary, NC,
USA). Since most of the U-EPX samples did not fit
a normal distribution, non-parametric tests were
used. To compare U-EPX samples among the RSV-
infected subjects with those of the age-matched
controls and among wheezers and non-wheezers,
Wilcoxon’s two-sample test was used. For an
evaluation of the U-EPX samples among RSV-
infected subjects at different times, Wilcoxon’smatched-pairs test was performed. The statistical
data are presented as the median and range.
A P-value o0.05 was regarded as statistically
significant.
Ethics
The project was approved by the Icelandic National
Ethics Committee. The participating parents signed
statements of informed consent.Results
U-EPX in the RSV group compared with
controls
At the time of inclusion, U-EPX levels were
comparable in the RSV group and the control group
(Fig. 1). At the follow-up after 3 months, at mean
age 6.4 months, the RSV group exhibited signifi-
cantly higher U-EPX values in relation to the
inclusion values (median 167.8; range 46.2–470.7
vs. 122.8; 43.7–266.0 mg/mmol creatinine; P ¼
0:023) (Fig. 1). U-EPX in the RSV group was also
significantly higher compared with age-matched 6-
month-old controls (167.8; 46.2–470.7 vs. 93.0;
19.0–204.0mg/mmol creatinine; P ¼ 0:0095) (Fig. 1).
There were no significant differences in U-EPX
between the two 3- and 6-month-old control
groups. Thirty months after inclusion, at mean
age 32.9 months, the U-EPX levels in the RSV group
were again comparable to the values at inclusion
(NS).Wheezing
At the follow-up visit 30 months after the bronch-
iolitis wheezing during the preceding 12 months
was evaluated in the RSV group. Sixty-five per cent
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(range) for the number of episodes of wheezing (for
children who had experienced wheezing) was 4
(1–12).
In the group of 18-month-old children without a
history of RSV bronchiolitis 48% (12/25) had
experienced wheezing during the preceding 12
months, median value for number of wheezing
episodes was 1 (1–5).U-EPX and wheezing
In the RSV group, a relationship was seen between
wheezing and U-EPX values at inclusion and at the
follow-up after 30 months. Subjects who had
experienced wheezing during the 12 months before
the follow-up had significantly higher U-EPX values
than non-wheezers, both at inclusion (165.7;
43.7–266.0 vs. 76.9; 58.6–137.4 mg/mmol creati-
nine; P ¼ 0:039) (Fig. 2) and 30 months later
(141.9; 63.0–264.0 vs. 59.9; 55.3–262.5 mg/mmol
creatinine; P ¼ 0:050). However, at the follow-up 3
months after inclusion, there was no difference in
U-EPX levels between future wheezers and non-
wheezers (167.8; 96.5–470.7 vs. 168.6; 46.2–
208.3 mg/mmol creatinine; P ¼ 0:51).Figure 2 Box and whisker plot of U-EPX at inclusion for
the RSV infected infants, divided by whether, by the visit
30 months after the bronchiolitis, they had (n ¼ 11) or
had not (n ¼ 6) experienced wheezing during the
preceding 12 months. Children with wheezing had
significantly higher U-EPX values, P ¼ 0:039. The boxes
show the 25th percentile, 50th percentile (median) and
75th percentile. The whiskers show the 10th percentile
(bottom) and 90th percentile (top). The square symbols
show mean values.Also, the children in the group of 18-month-old
children without a history of RSV bronchiolitis who
had wheezed during the preceding year had higher
U-EPX levels than those who had not wheezed
(138.5; 87.0–340.0 vs. 103.0; 19.0–197.0 mg/mmol
creatinine; P ¼ 0:030).Skin prick test
No children in the RSV group had a positive SPT at
the last visit, nor were any positive SPTs found in
the group of 18-month-old children from the Centre
for Child Health Services.White blood cell count
Three months after RSV infection eosinophils had a
median value (range) of 0.4 (0.1–0.7) 109/L vs.
0.25 (0.1–0.8) 109/L at inclusion, NS. However,
this 3-month follow-up value was significantly
higher than the 30-month follow-up value,
0.4 (0.1–0.7) 109/L vs. 0.2 (0–0.7) 109/L,
P ¼ 0:049. There were no statistically significant
differences in total white blood cell counts or
monocyte counts.Discussion
Compared with the inclusion values and compared
with the controls, a significant rise in U-EPX was
seen in the RSV group at the follow-up 3 months
after inclusion. This finding probably reflects an
ongoing eosinophil activation as a result of the RSV
infection. However, the increase was transient and
30 months later the values were comparable to
those at inclusion. Thus, the RSV infection does not
seem to have induced a persistent eosinophil
activation and the clinical significance of the
transient increase in U-EPX levels is therefore
uncertain. Regarding the eosinophil counts in
peripheral blood, the difference was not statisti-
cally significant between the values at inclusion
and at the follow-up 3 months later, but signifi-
cantly higher at that follow-up compared with the
follow-up at age 32.9 months. Largely, the changes
in U-EPX and eosinophils followed the same
pattern.
Many studies have reported an association
between RSV disease and childhood wheezing.1–3
In this limited material, at the follow-up 30 months
after inclusion 65% of the children in the RSV group
had experienced wheezing during the previous 12
months. This might, at least partly, represent an
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infection.
We compared the U-EPX values in the children who
subsequently wheezed in the RSV group with those
that did not. We found significantly higher U-EPX
inclusion values in the wheezing children. This
relationship was not apparent at the U-EPX peak 3
months after RSV infection, but was again significant
at the follow-up after 30 months. This is consistent
with the early results of Koller et al. and by Reijonen
et al., which indicated a possible predictive role for
S-ECP levels in the development of persistent
wheezing.10,11 In this context it is also of interest
to recollect that Ehlenfield et al. found that
eosinophilia at the time of RSV bronchiolitis gen-
erally predicted the development of wheezing
persisting into later childhood.12 Also, Øymar et al.
found a normal or high eosinophil count in infants
with severe viral wheeze to predict subsequent
recurrent wheezing, while U-EPX was not a pre-
dictive factor for recurrent wheezing in their study.13
U-EPX appears to have a baseline level, which is
individual for each child, as the values at inclusion
and at the follow-up 30 months later were
comparable. The wheezing children had signifi-
cantly higher EPX at inclusion as well as at the
follow-up 30 months later compared with those
who did not wheeze. Thus, in this study wheezing
seemed to correlate to baseline U-EPX levels. This
may explain why an association was not seen
between U-EPX values and wheezing 3 months
after RSV infection when the RSV infection probably
had induced a more generalized eosinophil activa-
tion. The finding of an association between baseline
U-EPX and wheezing may be consistent with a
hypothesis that RSV infection induces wheezing in
the genetically predisposed infant. Since it seems
to be an increased baseline U-EPX that shows
relationship to wheezing, perhaps that level is of
greater clinical interest than the transient increase
following infection.
The transient elevation of U-EPX at the follow-up
after 3 months seemed to be related to the RSV
infection since it was not seen in the group of age-
matched controls. In contrast, higher U-EPX levels
in children with wheezing were seen both in the
RSV group and in the randomly recruited group of
children aged 18 months. In the RSV group
significantly higher U-EPX values were seen already
at inclusion. Therefore, high U-EPX values may
indicate children prone to wheeze, possible identi-
fying future asthmatic children. This could be
interpreted to indicate that the relation between
high U-EPX values and inclination to wheezing was
independent of any risk of wheezing caused by the
RSV infection.Although atopic diseases were common among
parents and siblings in this study, no child in either
the RSV group or in the group of randomly recruited
18-month-old children exhibited a positive SPT. We
were surprised at this finding and we do not know if
this was due to chance or if positive SPTs just had
not yet developed at this young age. Whether RSV
bronchiolitis contributes to the subsequent devel-
opment of allergic sensitization is the subject of
debate. The Tucson study did not reveal any
correlation between LRTI and positive SPTs, or
differences in the mean total IgE between LRTI
subgroups.2 Stein et al. concluded that RSV infec-
tion was not correlated to the development of
atopic asthma or allergic sensitization. This can be
compared with the results of the Sigurs study,
which indicated that severe RSV infection in
infancy was an independent risk factor for the
development of asthma, as well as allergic sensi-
tization to aeroallergens at the age of 13 years.3
The subjects in the Tucson and Sigurs studies
differed substantially in terms of age at disease
onset and severity of illness. The children in the
Sigurs study had severe bronchiolitis while those in
the Tucson study were less severely ill. In the
present study the children were hospitalized but
not seriously ill. It is possible that the severity of
the initial disease may be important for the
development of asthma and/or allergy after RSV
infection. Furthermore, the age at disease onset
could influence disease outcome. The children in
the Sigurs long-term study were younger (mean age
4 months)3 than the subjects in the Tucson study
(o3 years).2 Mean age in the present study was 3.3
months.
A limitation of the present study is the relatively
small number of cases and controls. Furthermore,
ideally the same controls should have been fol-
lowed from the beginning of the study instead of
having two cross-sectional control groups. A long-
itudinally followed control group could also have
been used as control group at the follow-up of the
RSV group after 30 months. Although we were able
to perform comparisons within the group of
randomly recruited children aged 18 months, those
children could not be used as a proper control
group for the 30-month follow-up of the RSV group.
In conclusion, RSV bronchiolitis severe enough to
require in-ward care produces a significant yet
transient increase in U-EPX. Furthermore, subjects
in the RSV group who had experienced wheezing
during the year preceding the follow-up 30 months
after the bronchiolitis had significantly higher U-
EPX values both at inclusion and at that follow-up.
Thus, a high U-EPX at baseline appears to increase
the risk of future wheezing.
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